Pune, India, May 2023/MRFR Press Release/- Market Research Future has published its half-cooked research report on the global chlamydia infection treatment market.
According to MRFR analysis, the global chlamydia infection treatment market is expected to register a CAGR of ~9.80% from 2022 to 2030 and hold a value of USD 7.31 Billion by 2030.
The rise in sexually transmitted disease and increasing prevalence of chlamydia drives the growth of the chlamydia infection treatment market. Moreover, increasing awareness among the population for STDs and rising government initiatives to spread awareness for STDs is further driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), the chlamydial infection has the highest prevalence in people aged ≤24 years in the US. Moreover, asymptomatic infection is also very common among people. Therefore, annual screening of all sexually active women aged <25 years and older women at increased risk of infection is recommended.
Many market players are dominating the global chlamydia infection treatment market. The prominent players are involved in strategic agreements,product launches, and joint ventures to sustaintheir market positions.For instance,in 2019, Statens Serum Institut, completed clinical phase 1 trial for a first-generation vaccine candidate (CTH522), based on the major outer membrane protein of the C trachomatis bacterium. The vaccine will provide a promising preventive therapy for chlamydia infection.
By region, North America is anticipated to dominate the global chlamydia infection treatment market, owing to the well-established healthcare system, the high adoption rate in medical screening, and the presence of a high number of pharmaceutical and biopharmaceutical companies. Moreover, the high prevalence of STDs and rising government initiatives to spread awareness for STDs also drive the growth of the market.
On the other hand, the European chlamydia infection treatment market is driven by the rising R&D expenditure by biopharmaceutical companies, increasing investments in the R&D sector, and the presence of key market players.
Asia-Pacific is anticipated to be the fastest-growing region over the assessment period due to rapidly improving healthcare infrastructure, the rising pool of chlamydia-infected patients, wide adoption of STD screening, and the rapidly developing pharma and biopharma sector in the region.
Furthermore, the growth of the market in therest of the worldis attributed to the rising per capita expenditure of the population in the healthcare sector and the increasing adoption rate of medical screening inthe region.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Chlamydia Infection Treatment Market Research Report
The global chlamydia infection treatment market has been segmented into causative organisms, route of administration, and distribution channel.
By causative organisms, the market has been segregated into Chlamydia trachomatisand Chlamydia pneumoniae. The Chlamydia trachomatissegment held a significant share of the market in 2020 owing to the high prevalence of the disease.
Based on the route of administration, the global chlamydia infection treatment market has been classified as oral, injectable, and others. The oral route of administration is one of the most common and frequently used routes for drug administration and wasestimated to bethe largest segment in 2021.
Based on distribution channel,the chlamydia infection treatment market is classified into hospital pharmacy, online pharmacy, retail pharmacy,and others.Hospital pharmacy offers easy accessibility of medicines to patients and caters to a large patient pool. The increase in hospital admissions and a growing number of hospitals globally supports the growth of the segment.
Some of the key players in the global chlamydia infection treatment marketareMerck & Co. Inc. (US), Pfizer Inc (US), GlaxoSmithKline Plc (UK), AstraZeneca (UK), Gilead Sciences Inc.(US), Sanofi (France), Teva Pharmaceuticals (Israel), Sun Pharma (India), Eli Lilly and Company (US), Novartis (Switzerland), and others.